TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04734899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Strengthening with resistance bands for tibialis posterior, tibialis anterior, peroneus longus, finger flexors, hip and knee muscles, sheet gathering exercises, fingertip walking exercises, Stretching exercises for gastrocnemius and soleus muscles, plantar fascia stretching, weight transfer on one leg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Strengthening with resistance bands for tibialis posterior, tibialis anterior, peroneus longus, finger flexors, hip and knee muscles, sheet gathering exercises, fingertip walking exercises, Stretching exercises for gastrocnemius and soleus muscles, plantar fascia stretching, weight transfer on one leg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot core training
Description: Short foot exercises with passive modeling, active assisted modeling, active modeling, functional training
Study: NCT06044441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENABLE-SG model
Description: Patients and caregivers will receive individual structured psycho-educational sessions with a health coach. These sessions will be primarily delivered over the phone. Patient and caregiver dyads will have different health coaches. Patients will have six sessions on the topics of maintaining positivity, self-care, coping with stress, managing symptoms, exploring what matters most, and life review. Caregivers will have four sessions on the topics of maintaining positivity, self-care, coping with stress, and managing symptoms. All sessions will begin with screening for distress using the Distress Thermometer and Problem List culturally adapted from the National Comprehensive Cancer Network. From screening results, the health coach can flexibly change the order of the topics to address specific problems. It will take approximately three months to complete all sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: * 6-month wait-list control. Participants will receive the ENABLE-SG model six months after baseline (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~* Interventions: ENABLE-SG model
Study: NCT04784442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180mg of ETC-1002(bempedoic acid)
Description: 180mg, tablet, once daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120mg of ETC-1002(bempedoic acid)
Description: 120mg, tablet, once daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg of ETC-1002(bempedoic acid)
Description: 60mg, tablet, once daily, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, tablet, once daily, for 12 weeks
Study: NCT06515795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: In each arm, participants will execute an isometric exercise, in which they will perform 4 repetitions of 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: In each arm, participants will execute an isometric exercise, in which they will perform 4 repetitions of 2 minutes.
Study: NCT04813367

Intervention type: PROCEDURE
Intervention: Surgery of twisted fallopian tubes
Description: Patients diagnosed with twisted fallopian tube go through surgery.
Study: NCT05368701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volitional Help Sheet for self-harm
Description: The volitional help sheet (VHS) is a brief psychosocial intervention that significantly reduces thoughts and acts of self-harm in adults admitted to hospital following an initial episode of self-harm. It is based on IF-THEN statements that help people link critical situations to alternative appropriate responses. An example is: If I feel the urge to self-harm when I want to get relief from a terrible state of mind, then I will do something else instead of self-harming. IF-THEN statements are intended to act as automatic coping responses, especially in cases where people may feel the urge to self-harm.~The VHS has previously been successful in reducing self-harm in people recently admitted to hospital for self-harm. Recent data have also demonstrated that a web-based version of the VHS was acceptable among a large representative sample of UK adults with self-harm experiences. However, it is yet to be known whether this intervention is effective and acceptable among adolescents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet for self-harm
Description: The volitional help sheet (VHS) is a brief psychosocial intervention that significantly reduces thoughts and acts of self-harm in adults admitted to hospital following an initial episode of self-harm. It is based on IF-THEN statements that help people link critical situations to alternative appropriate responses. An example is: If I feel the urge to self-harm when I want to get relief from a terrible state of mind, then I will do something else instead of self-harming. IF-THEN statements are intended to act as automatic coping responses, especially in cases where people may feel the urge to self-harm.~The VHS has previously been successful in reducing self-harm in people recently admitted to hospital for self-harm. Recent data have also demonstrated that a web-based version of the VHS was acceptable among a large representative sample of UK adults with self-harm experiences. However, it is yet to be known whether this intervention is effective and acceptable among adolescents.
Study: NCT06156709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I: Lower Volume with Higher Anaesthetic Concentration
Description: 10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group II: Higher Volume with LowerAnaesthetic Concentration
Description: 20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
Study: NCT05466461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Beautifil Flow Plus X.
Description: Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel.Single Bond TM Universal will be applied to cavity walls and margins with agitation for 20 seconds.The adhesive will be light-cured for 20 seconds. Then Beautifil Flow Plus X composite will be placed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Activa bioactive restorative
Description: Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel. Bonding agent will be applied on the entire cavity and light-cured for 20 seconds then Activa bioactive restorative composite will be applied and cured for 20 seconds.
Study: NCT05654493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device
Description: The MicroPulse G-Probe was applied to the superior and inferior hemispheres of the eye under varied treatment times and sweep numbers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device
Description: The MicroPulse G-Probe was applied to the superior and inferior hemispheres of the eye under varied treatment times and sweep numbers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device
Description: The MicroPulse G-Probe was applied to the superior and inferior hemispheres of the eye under varied treatment times and sweep numbers
Study: NCT06191250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: one dose of durvalumab (750 mg IV)
Study: NCT06772454

Intervention type: DRUG
Intervention: Antitumor therapy
Description: All patients received suglizumab + paclitaxel + carboplatin:~Suglizumab 1200 mg IV Q3W Paclitaxel (albumin-bound) 100 mg/m2 IV, D1, 8, 15, Q3W Carboplatin AUC=5 mg/mL/min IV Q3W A total of 4 administration cycles were given, and Suglizumab 1200 mg IV Q3W was maintained after 4 administration cycles

Intervention type: DRUG
Intervention: Inhaled preparation for COPD
Description: 60 patients were randomly assigned to the following two groups in a 1:1 ratio, with about 30 patients in each group.~Group A: Receiving a long-acting beta-2 agonist (LABA) + a long-acting anticholinergic (LAMA) combination: Glonium bromide formoterol inhalation aerosol (7.2ug/5ug, trade name: Biwapin, Astrazeneca), 2 inhalations twice a day.~Group B: Received inhaled glucocorticoid (ICS) +LABA+LAMA as a three-drug combination: budesonide/glononium bromide/formoterol :160ug/7.2ug/4.8ug, Astrazeneca), 2 inhalations twice daily.
Study: NCT06191250

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-ablative oligofractionated radiation (NORT)
Description: 12 Gy of Radiation in 3 fractions
Study: NCT05067218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: buzzy device
Description: bee shaped with wings could be frozen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventinal anasthesia
Description: normal technique of injection
Study: NCT06773715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KindVR Aqua Program
Description: For this study, patients will be introduced to a virtual reality software program called Aqua, created by the company KindVR. This software program was designed specifically for use in pediatric patients. The software has been programmed into the Pico Neo 3 headset and provides an immersive 3D experience during which the patients explore a virtual underwater world inside a submarine with a goal of providing more color to treasure and different sea animals that they will engage with along their journey. The VR experience itself lasts approximately 15 minutes
Study: NCT06770114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride and Zinc Lactate Mouthwash
Description: 0 .075 % cetylpyridinium chloride and 0 .28 % zinc lactate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PhosFlur Mouthwash
Description: 0 .044 % sodium fluoride
Study: NCT06772363

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Raman spectroscopy intelligent diagnostic system
Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
Study: NCT06775119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test of neuromuscular fatigue and associated hemodynamic responses
Description: Baseline measurements of neuromuscular function and hemodynamic responses will be done. Investigators will then assess the mechanoreflex activation using the experimental technique of passive leg movement (PLM).~Following the PLM and the neuromuscular function baseline assessments, participants will perform four consecutive blocks, each consisting of a fatigue task followed by post-exercise circulatory occlusion (PECO). Neuromuscular function, assessed through maximal voluntary contraction (MVC) and quadriceps twitch techniques, will be measured before the fatigue task and after PECO in each block. Participants will perform 2-minutes isometric quadriceps sustained contraction at 20% MVC to induce exercise-induced neuromuscular fatigue. Hemodynamic responses will be measured during the PECO to isolate to the metaboreflex by inflating a cuff over the right thigh for a 2 minutes duration. After the PECO, the thigh cuff will be deflated, and neuromuscular function will be reassessed.
Study: NCT06775015

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Raman spectroscopy intelligent diagnostic system
Description: Serum Raman spectroscopy intelligent diagnostic system Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
Study: NCT06773832

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time Artificial Intelligence Model for Diagnosing Colorectal Polyp Pathology and Endoscopic Classification
Description: During the AI model development phase, the aim is to include as many samples as possible. Given the focus on the diagnostic accuracy of serrated lesions, we retrospectively collected approximately 400 cases serrated lesions with pathological diagnosis by the department of pathology at Peking Union Medical College Hospital to date. Additionally, we matched with 400 cases each of hyperplastic polyps, conventional adenomas, and early-stage colorectal cancer, totaling approximately 1600 cases.~The model employs mainstream AI classification algorithms to construct the model and compare the predictive performance of different models. Utilizing the dataset established in the first phase, which contains static images of polyp lesions along with their corresponding pathological diagnosis and endoscopic classifications, we developed and optimized the AI model. Then the model will be be compared with endoscopists in a prospective cohort to investigate the efficacy.
Study: NCT05622747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive heating
Description: 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C)
Study: NCT06386016

Intervention type: OTHER
Intervention: artificial intelligence-based stethoscope
Description: artificial intelligence-based stethoscope

Intervention type: OTHER
Intervention: artificial intelligence-based stethoscope
Description: artificial intelligence-based stethoscope
Study: NCT04659811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg given intravenously (IV) on day 1 (to -1) of radiation and then every 3 weeks until progression or unacceptable toxicity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Given in (a) single session treatment with margin dose of 15-20 Gy to the target for a maximum target volume of 8 cc or (b) five consecutive business days treatment to total dose of 25-30 Gy to the target for a maximum target volume of 20 cc when the target volume exceeds 8 cc or the target is in proximity to critical structures
Study: NCT05529095

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apomorphine Sublingual Film
Description: Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Sublingual Film
Description: Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill)
Study: NCT05266729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene Phosphatidylcholine
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene Phosphatidylcholine
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT05901844

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Paraffin pathological diagnosis
Description: Perform two diagnostic methods on the same sample
Study: NCT06179342

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple-Breath-Washout
Description: One additional diagnostic test is performed using the Multiple-Breath-Washout technology

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple-Breath-Washout
Description: One additional diagnostic test is performed using the Multiple-Breath-Washout technology
Study: NCT05422872

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.

Intervention type: OTHER
Intervention: Delphi study
Description: A Delphi study will be conducted with several rounds up to expert consensus.
Study: NCT06144580

Intervention type: OTHER
Intervention: Community Health and Wellbeing Worker
Description: Each CHWW will be deployed to cover 120 households in defined geographies ('villages') in North and South Westminster. LSOAs in the bottom 20% deprivation have been identified as priority areas for the CHWWs to be deployed. All households in the villages allocated to receive the intervention will be approached by the CHWW allocated to that village, irrespective of demographic characteristics and previous needs. CHWWs will visit all households each month, building a longitudinal relationship with each household so that problems arising from one month to the next can be captured in good time.
Study: NCT06067620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic right hemicolectomy
Description: Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section, using the Da Vinci Xi.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right hemicolectomy
Description: Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline.
Study: NCT05286645

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High definition transcranial direct current stimulation
Description: tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham high definition transcranial direct current stimulation
Description: Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
Study: NCT06770907

Intervention type: OTHER
Intervention: Blood, stool and saliva collection
Description: Blood, stool and saliva collection

Intervention type: OTHER
Intervention: Blood, stool and saliva collection
Description: Blood, stool and saliva collection

Intervention type: OTHER
Intervention: Blood, stool and saliva collection
Description: Blood, stool and saliva collection

Intervention type: OTHER
Intervention: Blood, stool and saliva collection
Description: Blood, stool and saliva collection

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Questionnaire on:~* Hospital Anxiety and Depression Score (HADS) for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Patient Health Questionnaire 12 (PHQ-12) Somatic Symptom scale
Study: NCT05807165

Intervention type: RADIATION
Intervention: Hypofractionated Stereotactic Radiotherapy (HF-SRT)
Description: The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.

Intervention type: RADIATION
Intervention: Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine
Description: * The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~* The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~  * During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed \[Week 1 -3\]~ * 5-mg twice a day in the following week \[Week 4\]~ * A morning dose of 10 mg and an evening dose of 5 mg in the following week \[Week 5\]~ * 10-mg twice a day for the subsequent weeks up to Week 24 \[Week 6 - 24\]
Study: NCT05923216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose OIT
Description: Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose OIT
Description: Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.